Wuhan Thalys Med Tech Co Ltd (603716) - Total Liabilities
Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has total liabilities worth CN¥753.10 Million CNY (≈ $110.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Wuhan Thalys Med Tech Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Wuhan Thalys Med Tech Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Wuhan Thalys Med Tech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Electric Terminal
KO:025540
|
Korea | ₩396.26 Billion |
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
USA | $1.53 Billion |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
China | CN¥548.79 Million |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
Germany | €314.48 Million |
|
Zhejiang Huakang Pharmaceutical Co Ltd
SHG:605077
|
China | CN¥4.32 Billion |
|
Hefei Lifeon Pharmaceutical Co Ltd
SHE:003020
|
China | CN¥663.27 Million |
|
Surfilter Network Technology Co Ltd
SHE:300311
|
China | CN¥549.85 Million |
|
Kearny Financial Corp
NASDAQ:KRNY
|
USA | $6.86 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Wuhan Thalys Med Tech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Wuhan Thalys Med Tech Co Ltd (603716) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Thalys Med Tech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Thalys Med Tech Co Ltd (2011–2025)
The table below shows the annual total liabilities of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥897.96 Million ≈ $131.40 Million |
-51.93% |
| 2024-12-31 | CN¥1.87 Billion ≈ $273.35 Million |
-7.85% |
| 2023-12-31 | CN¥2.03 Billion ≈ $296.63 Million |
-17.28% |
| 2022-12-31 | CN¥2.45 Billion ≈ $358.58 Million |
-3.93% |
| 2021-12-31 | CN¥2.55 Billion ≈ $373.24 Million |
+21.24% |
| 2020-12-31 | CN¥2.10 Billion ≈ $307.85 Million |
+51.79% |
| 2019-12-31 | CN¥1.39 Billion ≈ $202.82 Million |
+44.80% |
| 2018-12-31 | CN¥957.21 Million ≈ $140.07 Million |
+69.23% |
| 2017-12-31 | CN¥565.62 Million ≈ $82.77 Million |
+142.55% |
| 2016-12-31 | CN¥233.19 Million ≈ $34.12 Million |
+20.85% |
| 2015-12-31 | CN¥192.97 Million ≈ $28.24 Million |
+46.65% |
| 2014-12-31 | CN¥131.58 Million ≈ $19.25 Million |
+43.30% |
| 2013-12-31 | CN¥91.82 Million ≈ $13.44 Million |
-0.51% |
| 2012-12-31 | CN¥92.30 Million ≈ $13.51 Million |
+53.18% |
| 2011-12-31 | CN¥60.25 Million ≈ $8.82 Million |
-- |
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more